This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents
Amy Goodrich, MSN, CRNP
Johns Hopkins Kimmel Cancer Center
Dive into current strategies for managing patients with chronic lymphocytic leukemia and follicular lymphoma, including the risk-adapted treatment selection of new therapies based on factors such as patient age, performance status, and comorbidities. The latest data on the efficacy and safety of newly approved agents are presented, and strategies to treat common side effects reviewed.
These activities, certified for CME/CE/CPE credit, are jointly provided by
in collaboration with